Mark Fehr
Neurology · Baltimore, MDNPI 1275781338
Payments from drug & device makers
Across 196 payments — averaging $22.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$367
- UCB, Inc.$341
- SK Life Science, Inc.$271
- Lilly USA, LLC$219
- Pfizer$215
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,36398%
- Education$732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $1,160 |
| Novartis | 30 | $367 |
| UCB, Inc. | 13 | $341 |
| SK Life Science, Inc. | 9 | $271 |
| Lilly USA, LLC | 10 | $219 |
| Pfizer | 10 | $215 |
| Amgen(2 entities) | 8 | $208 |
| Neurelis, Inc. | 8 | $198 |
| Teva Pharmaceuticals USA, Inc. | 5 | $152 |
| Eisai Inc. | 6 | $146 |
| Lundbeck LLC | 4 | $115 |
| Supernus Pharmaceuticals, Inc. | 4 | $88 |
| Neurocrine Biosciences, Inc. | 3 | $87 |
| CSL Behring | 3 | $81 |
| Argenx US, Inc. | 2 | $70 |
| Biogen | 3 | $69 |
| Kyowa Kirin, Inc. | 3 | $69 |
| Ceribell, Inc. | 1 | $60 |
| Sanofi | 1 | $42 |
| Tanabe Pharma America, Inc. | 2 | $41 |
| Genentech USA, Inc. | 2 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| EMD Serono, Inc. | 1 | $29 |
| Amylyx Pharmaceuticals, Inc. | 1 | $29 |
| Catalyst Pharmaceuticals, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Insightec,inc | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Livanova USA, Inc. | 1 | $23 |
| Merz Pharmaceuticals, LLC | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
How this compares
$4,436 in reported general payments places this provider in the 55th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 11 | $88,193 |
| Nurtec OdtRimegepant Sulfate | 33 | $43,001 |
| Emgality PenGalcanezumab-Gnlm | 38 | $27,140 |
| Lacosamide | 131 | $20,035 |
| Topiramate ErTopiramate | 14 | $19,307 |
| Levetiracetam | 251 | $12,320 |
| Dimethyl Fumarate | 14 | $11,092 |
| Rivastigmine | 38 | $8,930 |
| Carbamazepine ErCarbamazepine | 43 | $6,845 |
| Memantine Hcl | 151 | $5,645 |
| Gabapentin | 124 | $3,184 |
| Donepezil Hcl | 197 | $2,494 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 18 | $2,411 |
| Oxcarbazepine | 11 | $1,738 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 81 | $1,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $69 | $88,19311 claims |
| PfizerNurtec Odt | $215 | $43,00133 claims |
| Lilly USA, LLCOlanzapine | $219 | $12720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 442 neurology providers in Maryland.
Other neurology in Baltimore
- Ellen MowryBaltimore$5.7M
- Michael PolydefkisBaltimore$4.1M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
- Nicholas MaragakisBaltimore$2.2M
- Shiv SaidhaBaltimore$2.1M
- Karisa SchreckBaltimore$1.9M
- Scott NewsomeBaltimore$1.7M
- Kathryn WagnerBaltimore$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.